Neurokinin B
Nootropic / cognitive
Cognition, mood, neuroprotection, or neuroplasticity support
Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.
Mechanism & Use
- Compound type
- Nootropic / neuroactive compound
- Primary mechanism
- Neurotransmitter, neurotrophic, or plasticity pathway modulation
- Primary market use
- Nootropic / cognitive
Pharmacology
- Molecular weight (Da)
- 1438.47
- Oral bioavailability
- Route-dependent / verify
- Half-life
- ~5–60 min parent peptide; analogs may be longer
- Route tags
- SubQ; Injectable; route-dependent
- Evidence level
- MCE product listing / research chemical signal
- Clinical status
- Research chemical/reference listing
- Value-for-money score
- 8 / 10
Reported protocol signal
No clean popular protocol found in uploaded sources; create as research/reference entry and verify before public protocol display.
For orientation only. See disclaimer — always consult a licensed clinician before use.
Stackability
Place in nootropic comparison clusters; track acute vs durable cognitive adaptation.
Notes
Neurokinin B TFA is a tachykinin family peptide that preferentially binds to and activates NK3R over other tachykinin receptors. Neurokinin B TFA preferentially binds to the substance P receptor ( SP-N receptor) and mediates acetylcholine release from cholinergic neurons. Neurokinin B TFA regulates the pulsatile release of Kisspeptin and GnRH , stimulates or inhibits the secretion of luteinizing hormone ( HY-P2293 ), regulates reproductive function via metabolic signals, and drives the onset of ...